Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorecivivint - Samumed

Drug Profile

Lorecivivint - Samumed

Alternative Names: Adavivint; SM-04690

Latest Information Update: 24 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samumed
  • Class Anti-inflammatories; Antirheumatics; Imidazoles; Indazoles; Pyridines; Small molecules
  • Mechanism of Action Clk dual-specificity kinase inhibitors; DYRK kinase inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Phase I Intervertebral disc degeneration

Most Recent Events

  • 01 May 2019 Phase-III STRIDES-X-ray clinical trial in Osteoarthritis in USA (Intra-articular) (NCT03928184)
  • 23 Apr 2019 Samumed terminates a phase I trial in Intervertebral disc degeneration in USA, due to business reasons (NCT03246399)
  • 11 Apr 2019 Efficacy data from a phase IIb trial in osteoarthritis released by Samumed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top